All eyes on preliminary results from key COVID-19 drug ‘remdesivir’ trial
Washington: After witnessing a controversial 'inconclusive' report last week, all eyes are now on preliminary results from a key global trial of US-based Gilead Sciences' remdesivir, a potential antiviral drug to treat COVID-19, that will…
Read More...
Read More...